MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co. discovers and develops proprietary human monoclonal antibody products for the diagnosis and treatment of a variety of cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center and are licensed to Co.'s subsidiary, MabVax Therapeutics, Inc. Co.'s development program is centered around its HuMab-5B1 antibody, which is discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial. The antigen the antibody targets is expressed on pancreatic cancers, small cell lung cancer, stomach, colon and other cancers. We show 2 historical shares outstanding datapoints in our coverage of MBVX's shares outstanding history.
Understanding the changing numbers of MBVX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MBVX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MBVX by allowing them to research MBVX shares outstanding history
as well as any other stock in our coverage universe. |
Free MBVX Email Alerts:
Video: Shares Outstanding Importance
